1. Search Result
Search Result
Isoforms Recommended: IL-5
Results for "

IL5

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

2

Biochemical Assay Reagents

2

Peptides

1

MCE Kits

17

Inhibitory Antibodies

7

Natural
Products

31

Recombinant Proteins

8

Antibodies

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9945

    SB 240563

    Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-P9945A

    Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-P990774

    ASP-7266; TRAB-1; UPB-101

    Interleukin Related Inflammation/Immunology
    Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
    Verekitug
  • HY-19969
    YM-90709
    1 Publications Verification

    Interleukin Related Inflammation/Immunology
    YM-90709 is a novel IL-5 inhibitor which selectively blocks the binding of IL-5 to the IL-5 receptor (IL-5R).YM-90709 potently inhibits the binding of [ 125I]-IL-5 to IL-5R on human peripheral eosinophils and eosinophilic HL-60 clone 15 cells with IC50 values of 1.0 and 0.57 μM .
    YM-90709
  • HY-N1938

    D-Raffinose pentahydrate

    Endogenous Metabolite Glucosylceramide Synthase (GCS) Bacterial Phosphodiesterase (PDE) Interleukin Related Infection Inflammation/Immunology
    D(+)-Raffinose pentahydrate is an orally active inhibitor of LecA (Kd = 32 μM) and GtfC. D(+)-Raffinose pentahydrate reduces cyclic diguanylate (c-di-GMP) by increased activity of a c-di-GMP specific phosphodiesterase. D(+)-Raffinose pentahydrate interferes with GTF function. D(+)-Raffinose pentahydrate decreases IL-4 and IL-5 mRNA. D(+)-Raffinose pentahydrate exhibits biofilm-inhibitory activity against Pseudomonas aeruginosa and Streptococcus mutans and inhibits allergic airway eosinophilia .
    D(+)-Raffinose pentahydrate
  • HY-137131

    DC-Cholesterol hydrochloride

    Amyloid-β Liposome IFNAR Interleukin Related Neurological Disease Inflammation/Immunology
    DC-Chol hydrochloride is a cationic lipid. DC-Chol hydrochloride could inhibit Aβ40 fibril formation under appropriate experimental conditions. DC-Chol hydrochloride strongly inhibits amyloidogenesis of oxidized hCT in a dose-dependent manner. DC-Chol hydrochloride induces the production of Th1 (IL-2 and IFN-γ) and Th2 (IL-5) cytokines. DC-Chol hydrochloride can enhance the body's immune response to antigens. DC-Chol hydrochloride is used as a gene delivery vector. DC-Chol hydrochloride can be used in research in areas such as hepatitis B vaccines to improve vaccine immunity .
    DC-Chol hydrochloride
  • HY-P9923A
    Benralizumab (anti-IL5RA )
    1 Publications Verification

    MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )

    Interleukin Related Apoptosis Inflammation/Immunology
    Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA)) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
    Benralizumab (anti-IL5RA )
  • HY-N0646
    Silydianin
    1 Publications Verification

    Phosphatase Endogenous Metabolite Tyrosinase Apoptosis Interleukin Related Inflammation/Immunology Cancer
    Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research [5] .
    Silydianin
  • HY-P990748

    SAR443765

    Interleukin Related Inflammation/Immunology
    Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma .
    Lunsekimig
  • HY-P990213

    Interleukin Related Inflammation/Immunology
    Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived anti-mouse IL-5 IgG1 κ type antibody inhibitor. Anti-Mouse/Human IL-5 Antibody (TRFK5) can significantly decrease eosinophils. Anti-Mouse/Human IL-5 Antibody (TRFK5) shows potent anti- inflammation effect on pulmonary inflammation and asthma .
    Anti-Mouse/Human IL-5 Antibody (TRFK5)
  • HY-NP159

    Mucin Interleukin Related Inflammation/Immunology
    House Dust Mite Extract, from D.farinae is a house dust mite allergen extract derived from Dermatophagoides farinae. House Dust Mite Extract, from D.farinae significantly increases the levels of cytokines (IL-4, IL-5, IL-6) in bronchoalveolar lavage fluid. House Dust Mite Extract, from D.farinae upregulates the overexpression of MUC5AC. House Dust Mite Extract, from D.farinae induces allergic asthma and pulmonary inflammation .
    House Dust Mite Extract, from D.farinae
  • HY-P9949

    Sch 55700; CDP-835; JES1-39D10

    Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
    Reslizumab
  • HY-17002
    Suplatast (Tosilate)
    1 Publications Verification

    IPD 1151T

    Interleukin Related Inflammation/Immunology
    Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity .
    Suplatast (Tosilate)
  • HY-P99371

    AK002; Antolimab

    Apoptosis Inflammation/Immunology
    Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
    Lirentelimab
  • HY-P1111

    Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy .
    Lyn peptide inhibitor
  • HY-N6013

    MMP Proteasome Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Bacterial Fungal Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .
    Aloin (mixture of A&B)
  • HY-P990094

    CSL311

    c-Fms Inflammation/Immunology
    Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .
    Trabikibart
  • HY-P9923
    Benralizumab
    1 Publications Verification

    MEDI-563; BIW-8405; KHK4563

    Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
    Benralizumab
  • HY-P99850

    GSK-3511294

    Interleukin Related Inflammation/Immunology
    Depemokimab (GSK-3511294) is a long-acting anti-IL-5 monoclonal antibody. Depemokimab can be used for research of asthma .
    Depemokimab
  • HY-N8309

    Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
    Luteolin-4'-O-glucoside
  • HY-110295

    GSNOR Inflammation/Immunology
    SPL-334 is a potent and selective S-Nitrosoglutathione reductase (GSNOR) inhibitor. SPL-334 causes a significant reduction in the production of Th2 cytokines IL-5 and IL-13 and the levels of the chemokine CCL11 (eotaxin-1) in the airways. SPL-334 can be used in research of allergic airway inflammation .
    SPL-334
  • HY-111167

    Phosphodiesterase (PDE) Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research .
    AN-2898
  • HY-175876

    MMP Interleukin Related Inflammation/Immunology
    ADAM17-IN-1 is a selective inhibitor of ADAM17. ADAM17-IN-1 inhibits ADAM17 activity to reduce metabolic activity of dendritic cells (DCs), impair DC antigen-presenting function, suppress allergen-specific Th2 cell polarization, and reduce Th2 cytokine (IL-4, IL-5, IL-13) secretion. ADAM17-IN-1 demonstrates protective efficacy against house dust mite (HDM)-induced type 2/eosinophilic airway inflammation in mice. ADAM17-IN-1 can be used for the study of type 2-high allergic asthma .
    ADAM17-IN-1
  • HY-RS06771

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5 Mouse Pre-designed siRNA Set A
    Il5 Mouse Pre-designed siRNA Set A
  • HY-RS06770

    Small Interfering RNA (siRNA) Interleukin Related Others

    IL5 Human Pre-designed siRNA Set A contains three designed siRNAs for IL5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL5 Human Pre-designed siRNA Set A
    IL5 Human Pre-designed siRNA Set A
  • HY-P991712

    Interleukin Related Inflammation/Immunology
    Revbekitug is a humanized IgG1κ antibody targeting IL-5. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Revbekitug
  • HY-RS06772

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Il5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5 Rat Pre-designed siRNA Set A
    Il5 Rat Pre-designed siRNA Set A
  • HY-P991633

    Interleukin Related Inflammation/Immunology
    TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .
    TQC2938
  • HY-19486

    Nuclear Factor of activated T Cells (NFAT) CD3 CD28 Interleukin Related Inflammation/Immunology
    UR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27 KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis .
    UR-1505
  • HY-174602

    mRNA Inflammation/Immunology
    Human IL5 mRNA encodes the human interleukin 5 (IL5) protein, a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. IL5 plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases.
    Human IL5 mRNA
  • HY-106979

    SAR-943

    Drug Derivative Interleukin Related Inflammation/Immunology
    Olcorolimus (SAR-943) is a Rapamycin (HY-10219) derivative. Olcorolimus can reduce IL-4, IL-5, eosinophil, neutrophil, lymphocyte, cellular fibronectin; lung epithelial cell proliferation and mucus hypersecretory phenotype in Ovalbumin (HY-W250978)-sensitized BALB/c mice. Olcorolimus can be used for the researches of inflammation and immunology, such as asthma .
    Olcorolimus
  • HY-P1111A

    Src Interleukin Related Inflammation/Immunology
    Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders .
    Lyn peptide inhibitor TFA
  • HY-147660

    LPL Receptor Inflammation/Immunology
    IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research .
    IMMH001
  • HY-W585843

    Interleukin Related Inflammation/Immunology
    1,1′-Ethylidenebis[L-tryptophan] is an impurity in the synthesis of L-tryptophan. 1,1′-Ethylidenebis[L-tryptophan] promotes the proliferation of eosinophilic leukemia cells, induces the release of eosinophil cationic protein from eosinophils, and stimulates T cells to produce IL-5. 1,1′-Ethylidenebis[L-tryptophan] (40 µg/kg) can induce fascia thickening, mast cell infiltration, and fibrosis in adipose and subcutaneous muscle tissues in mice. 1,1′-Ethylidenebis[L-tryptophan] can be used in immunology and inflammation research .
    1,1′-Ethylidenebis[L-tryptophan]
  • HY-P991144

    Interleukin Related Inflammation/Immunology
    Lasrekibart is a humanized monoclonal antibody targeting human interleukin 5 (IL-5). Lasrekibart specifically binds to IL-5, blocking the interaction between IL-5 and its receptor, thus exerting immunosuppressive and anti-inflammatory activities. Lasrekibart is promising for research of allergic and inflammatory diseases, such as asthma .
    Lasrekibart
  • HY-P990058

    Interleukin Related Inflammation/Immunology
    Varokibart (TEV-53275) is a human IgG4λ antibody targeting IL5 .
    Varokibart
  • HY-19472

    Ser/Thr Protease Inflammation/Immunology
    RWJ-58643 is a β-trypsin inhibitor that suppresses allergic inflammation. RWJ-58643 (100 mg) significantly reduced nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses. RWJ-58643 resulted in late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). RWJ-58643 modulates allergic responses by inhibiting the release of β-trypsin from mast cells .
    RWJ-58643
  • HY-19472A

    Ser/Thr Protease Inflammation/Immunology
    RWJ-58643 hydrochloride is a β-trypsin inhibitor that inhibits allergic inflammation. RWJ-58643 hydrochloride (100 mg) significantly reduces nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses. RWJ-58643 hydrochloride causes late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). RWJ-58643 hydrochloride modulates allergic reactions by inhibiting the release of β-trypsin from mast cells.
    RWJ-58643 hydrochloride
  • HY-P991599

    Interleukin Related Inflammation/Immunology
    SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. SHR-1703 can selectively recognize and bind to IL-5, blocking the binding of IL-5 to the α chain of the receptor on the surface of eosinophils, thereby inhibiting the proliferation, activation, and migration of eosinophils, and ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 can be used in the research of eosinophil-related diseases, such as eosinophilic asthma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    SHR-1703
  • HY-N8309R

    Reference Standards Interleukin Related Inflammation/Immunology Cancer
    Luteolin-4'-O-glucoside (Standard) is the analytical standard of Luteolin-4'-O-glucoside. This product is intended for research and analytical applications. Luteolin-4'-O-glucoside is an IL-5 inhibitor with an IC50 of 3.7 μM. Luteolin-4'-O-glucoside resists hyperuricemia and acute gouty arthritis activity. Luteolin-4'-O-glucoside shows anticancer activity .
    Luteolin-4'-O-glucoside (Standard)
  • HY-N6013R

    Reference Standards Proteasome MMP Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Fungal Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aloin (mixture of A&B) (Standard) is the analytical standard of Aloin (mixture of A&B) (HY-N6013). This product is intended for research and analytical applications. Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .
    Aloin (mixture of A&B) (Standard)
  • HY-169864

    LPL Receptor Inflammation/Immunology
    KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .
    KRO-105714
  • HY-165484

    Interleukin Related Inflammation/Immunology
    AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .
    AVP-13358
  • HY-N0646R

    Reference Standards Phosphatase Endogenous Metabolite Tyrosinase Apoptosis Interleukin Related Inflammation/Immunology Cancer
    Silydianin (Standard) is the analytical standard of Silydianin (HY-N0646). This product is intended for research and analytical applications. Silydianin is a flavonolignan. Silydianin can be obtained from Silybum marianum. Silydianin inhibits PTP1B with an IC50 of 17.38 μM. Silydianin inhibits both monophenolase and diphenolase of tyrosinase significantly, with IC50s of 2.6 μM and 16.5 μM, respectively. Silydianin induces Apoptosis and reduces cytokines (IL-4 and IL-5). Silymarin has antioxidant, cytoprotective and immunomodulatory effects. Silydianin has antitumor activity against prostate cancer. Silymarin can be used in allergic asthma research [5] .
    Silydianin (Standard)
  • HY-174601

    mRNA Inflammation/Immunology
    Human IL5RA mRNA encodes the human interleukin 5 receptor subunit alpha (IL5RA) protein, an interleukin 5 specific subunit of a heterodimeric cytokine receptor. IL5RA has been found to interact with syndecan binding protein (syntenin), which is required for IL5 mediated activation of the transcription factor SOX4.
    Human IL5RA mRNA
  • HY-P990452

    Interleukin Related Inflammation/Immunology
    Anti-IL-5 Antibody is a CHO-expressed humanized antibody that targets IL-5. The Anti-IL-5 Antibody is composed of huIgG4 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-IL-5 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-IL-5 Antibody
  • HY-RS06773

    Small Interfering RNA (siRNA) Others

    IL5RA Human Pre-designed siRNA Set A contains three designed siRNAs for IL5RA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL5RA Human Pre-designed siRNA Set A
    IL5RA Human Pre-designed siRNA Set A
  • HY-182795

    MMP Interleukin Related TGF-beta/Smad Metabolic Disease
    Colchicine derivative-1 is a colchicine derivative. Colchicine derivative-1 exhibits cytotoxicity against various cells. Colchicine derivative-1 arrests cancer cells at the G2/M phase of the cell cycle. Colchicine derivative-1 increases the levels of MMP-2, MMP-8, MMP-9, IL-2, IL-6, IL-17A, IL-22, IL-4, and IL-5 in the blood, inhibits the gene expression of hepatic fibrinogen α, β, γ and TGF-β1, and alleviates hepatic fibrosis symptoms in mice. Colchicine derivative-1 has antifibrotic activity and can be used in studies related to hepatic fibrosis .
    Colchicine derivative-1
  • HY-RS26191

    Small Interfering RNA (siRNA) Others

    Il5ra Rat Pre-designed siRNA Set A contains three designed siRNAs for Il5ra gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5ra Rat Pre-designed siRNA Set A
    Il5ra Rat Pre-designed siRNA Set A
  • HY-RS19696

    Small Interfering RNA (siRNA) Others

    Il5ra Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il5ra gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il5ra Mouse Pre-designed siRNA Set A
    Il5ra Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: